분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2010-03-23 09:03:36 , Hit : 2908
 More support for RNAi in clinic

Posted by Edyta Zielinska
[Entry posted at 21st March 2010 06:02 PM GMT]
Comment on this news story    

Nanoparticles studded with short RNA molecules can silence target genes in melanoma patients, demonstrating the clinical feasibility of these techniques for the first time, according to research published online today (March 21) in Nature.


Nanoparticles
Image: Wikimedia/Nandiyanto
"This is a breakthrough for the field," said John Rossi from the City of Hope Cancer Center, who was not involved in the study. It's the first clinical proof that "RNA is entering the tumor cells and delivering the goods" needed to reduce the expression of target cancer-genes, he said.

While the result is clearly a boon for the fields of RNA interference (RNAi) and nanobiology, it remains to be seen whether the new therapy improves patient outcomes, scientists said.

RNAi functions by binding to the mRNA transcript of a gene before it is translated into a protein and cutting it at a specific point in the sequence, thereby reducing the amount of protein the gene can produce. Earlier trials for other diseases had injected patients with short interfering RNAs (siRNAs), resulting in improved patient health. But whether this improvement was the result of the siRNA-induced gene knockdown or a product of immune system activation due to the presence of the siRNA molecules in the bloodstream, which the body recognizes as a sign of infection, was unclear.

To get to the bottom of this question, Mark Davis from the California Institute of Technology and colleagues attached the siRNAs to nanoparticles, which effectively hide the genetic material from the immune system. The researchers also attached a ligand for a receptor that is more abundant on cancer cells to ensure that the nanoparticles were taken up predominantly by those cells. Once inside, the nanoparticles are designed to disintegrate, releasing their siRNA payload into the cells.

As part of a Phase I human clinical trial, the team looked at cancer samples of three melanoma patients injected with the siRNA-studded nanoparticles. Over several treatments, the researchers observed an increasing accumulation of the particles and a corresponding reduction in the levels of the mRNAs and proteins targeted by the siRNAs, suggesting that the siRNAs successfully interfered with gene expression in the cancer cells.

The results are "important because delivery [of the siRNAs] is the major obstacle to therapeutics," said Judy Lieberman of Harvard Medical School, who writes about RNAi in the upcoming April issue of The Scientist. "I was impressed with the degree of [mRNA] knock-down that they were able to achieve," she added.

In addition, the presence of mRNA fragments cut at the intended location indicated that the siRNA was functioning inside the cell as expected. "That's why this study is beautiful," said Sancy Leachman, a physician scientist at the University of Utah Health Sciences Center. "The mRNA is clipped in the right spot."

The study did not, however, provide an indication that the therapy was controlling the cancer, Lieberman said. "Were there fewer dividing cells, [and/or] was there any apoptosis [in the cancer cells]?," she asked. The study did not show evidence of either, and the results from the clinical study, including the results from about 12 additional patients with a variety of cancers, aren't expected for several months at least, Davis said.

Because both the receptor ligand that helps the nanoparticles traffic to cancer cells, and the gene that is targeted for knockdown by siRNA "are fairly ubiquitous" across cancer types, this therapy has the potential to work in many cancer types, said Davis. But some cancers are more or less dependent on this particular gene for survival; thus they may not be as susceptible to the genetic knock-down as others. "Ultimately we'd want a more specific targeting ligand and more specific genes," said Davis.

Still, "this is a very, very exciting finding," said Leachman. "This was a proof of principle experiment in a person," that demonstrated the feasibility of the approach.




Read more: More support for RNAi in clinic - The Scientist - Magazine of the Life Sciences http://www.the-scientist.com/blog/display/57226/#ixzz0ixAFoSfK







947   Merck’s Hepatitis C Drug Wins F.D.A. Approval  이성욱 2011/05/17 2291
946   Mice Get Human Livers  이성욱 2010/02/24 4444
945   Microbe gets toxic response  이성욱 2010/12/10 2471
944   microRNA Discovery Might Help ALS Patients  이성욱 2009/12/14 4787
943   MicroRNAs Prevent Cell Reprogramming  이성욱 2011/10/27 3643
942   microRNA가 췌장암 치료제가 될 수 있을까  이성욱 2015/06/30 1179
941   MicroRNA를 매개하여 C형 간염을 치료하는 인터페론  이성욱 2007/10/25 4724
940   Minimal Genome Created  이성욱 2016/03/26 965
939   miRNA로 암줄기세포를 통제한다  이성욱 2007/12/20 5130
938   miRNA를 이용한 계통발생 분석의 문제점  이성욱 2014/08/01 1727
937   miRNA를 이용한 암살상바이러스의 지향성(tropism) 강화  이성욱 2008/11/01 4731
936   miRNA를 침묵시켜 C형간염을 치료  이성욱 2009/12/07 4704
935   miRNA와 Ago2에 의한 혈구세포의 발달과정 규명  이성욱 2007/08/02 5894
934   miro RNA  정흥수 2003/09/01 3983
933   Missing Molecules Hold Promise of Therapy for Pancreatic Cancer: Lost microRNAs Put Brakes on Tumors  이성욱 2010/12/22 2272
932   MIT 선정 2015년 주목받은 Biomedicine 뉴스  이성욱 2016/02/03 1008
931   Molecular discovery suggests new strategy to fight cancer drug resistance  이성욱 2010/06/25 2386
930   Molecular Mechanism Triggering Parkinson's Disease Identified - miRNA  이성욱 2010/08/02 2474
929   Molecular scalpel hope for Duchenne muscular dystrophyBy James Gallagher  이성욱 2011/07/28 2942
  More support for RNAi in clinic  이성욱 2010/03/23 2908

[이전 10개] [1]..[11][12][13][14][15][16] 17 [18][19][20]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN